Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Recruiting
This phase II trial studies how well abemaciclib works in treating patients with triple negative breast cancer that can be removed by surgery (resectable) and does not respond to treatment with chemotherapy alone, or in combination with pembrolizumab. Abemaciclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/16/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Fibrocystic Change, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Parenting Mindfully Study II
Recruiting
This study will conduct a large Randomized Controlled Trial to test effects of a parenting mindfully (PM) intervention versus a parent education (PE) intervention for highly stressed parents of adolescents.
Gender:
ALL
Ages:
Between 12 years and 14 years
Trial Updated:
08/16/2024
Locations: George Mason University, Fairfax, Virginia
Conditions: Adolescent Substance Use, Adolescent Psychological Symptoms, Parent Stress, Parenting
Disparities in Emergency Contraceptive Metabolism Dictate Efficacy
Recruiting
The purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
08/16/2024
Locations: OHSU, Portland, Oregon
Conditions: Contraceptive Usage
Texting to Reduce Human Immunodeficiency Virus (HIV) Risk
Recruiting
This is a 3-year study to test the efficacy of a text message-based intervention program. Dental patients at 4 community health centers (n= 266) will be randomized to receive either text messages (TMs) regarding HIV prevention or TMs regarding overall wellness. Prior to enrolling the 266 participants, the investigators will conduct a feasibility pilot (n=20) to test the TM delivery as well as all study procedures. For both the pilot and the randomized clinical trial (RCT), recruitment will be co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2024
Locations: South End Community Health Center, Boston, Massachusetts +1 locations
Conditions: HIV Infections
Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
Recruiting
The purpose of this study is to evaluate the safety and efficacy of a single injection of IP-001 as adjuvant therapy after local ablation or surgical resection and ablation in patients with hepatocellular carcinoma (HCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2024
Locations: University of Louisville, Louisville, Kentucky
Conditions: Hepatocellular Carcinoma
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Recruiting
The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2024
Locations: City of Hope, Duarte, California +2 locations
Conditions: T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma
Arizona Alzheimer's Disease Research Center (ADRC)
Recruiting
The Arizona Alzheimer's Disease Research Center (ADRC) is the National Institute on Aging's (NIA's) first statewide AD Center (ADC), the only ADC in the Southwestern United States, and a leading example of statewide collaboration in biomedical research. It capitalizes on Arizona's strengths in brain imaging, genomics, computer science and biomathematics, the basic, cognitive and behavioral neurosciences, clinical, and neuropathological studies of AD, the discovery and evaluation of investigation... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/16/2024
Locations: Banner Alzheimer's Institute, Phoenix, Arizona +4 locations
Conditions: Alzheimer Disease
Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients
Recruiting
This clinical trial studies how well 3-dimensional multi-parametric ultrasound (3D MPUS) imaging works as a decision-support tool for patients with liver tumors undergoing therapy. Continuous and dynamic imaging of patients undergoing therapy is required to monitor early-phase treatment response. 3D-MPUS is an inexpensive and safe method, which may provide complementary quantitative functional (perfusion) and tissue characterization information to anatomical radiological assessment or blood biom... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2024
Locations: Stanford University, School of Medicine, Palo Alto, California +1 locations
Conditions: Liver Cancer, Adult
Young Adult Tobacco/Nicotine and Cannabis Co-use
Recruiting
The goal of this project is to better understand the relationship between tobacco/nicotine and cannabis using behavioral economics during a tobacco/nicotine quit attempt. All participants will receive tobacco/nicotine cessation treatment (smoking and/or vaping treatment) for 12 weeks. To qualify, participants must be between the ages of 18-25 and use tobacco products (smoke cigarettes and/or vape nicotine) and use cannabis (in any form). Participants do not need to be interested in quitting cann... Read More
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
08/16/2024
Locations: Medical University of South Carolina - Charleston, Charleston, South Carolina
Conditions: Tobacco Use Disorder, Nicotine Dependence
Treatment Optimization of Brain-injured Warfighters
Recruiting
Prescribed sub-symptomatic adaptable exercise treatment (SAET) is a potential solution that promotes recovery needs following a TBI. SAET has been shown to benefit the mind and body in ways that decrease the severity and frequency of mild TBI (mTBI) symptoms. This study aims to validate SAET as an alternative, adaptable treatment or SMs with mTBI that focuses on reducing symptoms, improving mental health, increasing physiological functioning, and ultimately returning to duty. The objective of t... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/16/2024
Locations: Intrepid Spirit Center, Camp Pendleton, California
Conditions: Mild Traumatic Brain Injury
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
Recruiting
The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, reduced risks of contagious infections, and the availability for immediate use. The UCB transplant is also associated with a lower incidence of graft versus host disease, or GvHD (in GvHD, the transplanted graft attacks the recipient organs).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/15/2024
Locations: University of Rochester, Rochester, New York
Conditions: AML, NHL, Hodgkin Disease, All, Myelodysplastic Syndrome
High Dose Omeprazole in Patients With Pancreatic Cancer
Recruiting
The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/15/2024
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Exocrine Pancreatic Cancer